Global Peptide Therapeutics Industry: Key Statistics and Insights in 2024-2032

Summary:

• The global peptide therapeutics market size reached USD 42.8 Billion in 2023.
• The market is expected to reach USD 86.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.
• North America leads the market, accounting for the largest peptide therapeutics market share.
• Innovative holds the majority of the market share in the type segment. 
• In-house dominates the peptide therapeutics industry.
• Liquid phase peptide synthesis is the leading segment in the market, driven by its flexibility and efficiency in producing a wide range of peptide sequences.
• Parenteral represents the biggest application segment.
• Cancer exhibits a clear dominance in the market.
• The increasing prevalence of chronic diseases and cancer is a primary driver of the peptide therapeutics market.
• Technological innovation in synthesis and the growing focus on personalized medicine are reshaping the peptide therapeutics market.

Industry Trends and Drivers:

• Rising prevalence of chronic diseases and cancer:

The increasing cases of chronic diseases, such as diabetes, cardiovascular disorders, and cancer, among the masses represents one of the major factors impelling the market growth. These conditions often require targeted therapies, and peptides, with their high specificity and low toxicity, offer improved solutions. In cancer treatment, peptide-based drugs can target tumors selectively, reducing side effects commonly associated with conventional chemotherapy. Additionally, peptides play a vital role in managing metabolic and hormonal disorders, where they can mimic or influence natural bodily functions, enhancing therapeutic efficacy. The growing prevalence of lifestyle-related diseases like diabetes further underscores the need for peptide-based treatments, as peptides can mimic insulin action or influence glucose metabolism.

• Technological innovations in peptide synthesis:

Traditional methods of peptide synthesis were often labor-intensive and time-consuming, leading to high production costs and limited scalability. However, innovations in solid-phase peptide synthesis (SPPS) and automated synthesizers are transforming the landscape, allowing for rapid and cost-effective production of high-quality peptides. These advancements not only enhance the yield and purity of peptide products but also enable the synthesis of complex peptides with higher specificity and functionality. Additionally, new techniques, such as microwave-assisted synthesis and click chemistry, are streamlining the development of novel peptide-based therapeutics. Production is becoming more efficient and cost-effective, which is improving the accessibility of peptide therapies. The continuous development of peptide synthesis technologies is expanding the pipeline of peptide therapeutics, catering to various therapeutic areas.

Growing focus on personalized medicine:

Healthcare is moving away from one-size-fits-all approaches, which is driving the demand for targeted and customized therapies. Peptides, due to their unique ability to interact with specific biological pathways, allow for the development of tailored treatments that address the unique genetic and molecular profiles of patients. This customization enhances therapeutic efficacy and reduces adverse effects, making peptide therapies particularly appealing for conditions like cancer, where individual tumor characteristics can greatly influence treatment outcomes. The trend of personalized medicine is supported by advancements in genomics and proteomics, which facilitate the identification of novel peptide targets. Healthcare systems are recognizing the value of personalized treatment strategies, which is leading to higher investment in peptide therapeutics to encourage further innovation in this field.

Request for a sample copy of this report: https://www.imarcgroup.com/peptide-therapeutics-market/requestsample

Peptide Therapeutics Market Report Segmentation:

Breakup By Type:

• Innovative
• Generic

Innovative exhibits a clear dominance in the market, driven by the advanced therapeutic potential and higher investment in research operations.

Breakup By Type of Manufacturer:

• Outsourced
• In-house

In-house represents the largest segment due to the preference of companies to maintain control over production quality and intellectual property.

Breakup By Synthesis Technology:

• Solid Phase Peptide Synthesis
• Liquid Phase Peptide Synthesis
• Hybrid Technology

Liquid phase peptide synthesis holds the biggest market share attributed to its flexibility and efficiency in producing a wide range of peptide sequences.

Breakup By Routes of Administration:

• Parenteral
• Oral
• Others

Parenteral accounts for the majority of the market share, as it offers direct and efficient delivery of peptides that are otherwise poorly absorbed orally.

Breakup By Application:

• Gastrointestinal Disorders
• Neurological Disorders
• Metabolic Disorders
• Cancer
• Others

Cancer represents the largest segment accredited to the rising demand for targeted therapies and the increasing investment in oncology research.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the market owing to its advanced healthcare infrastructure, high investments in research, and the presence of major pharmaceutical companies.

Top Peptide Therapeutics Market Leaders:

The peptide therapeutics market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Amgen Inc.
• Apitope International NV
• Arch Biopartners Inc.
• AstraZeneca plc
• Circle Pharma Inc.
• Corden Pharma GmbH
• F. Hoffmann-La Roche AG
• Ipsen Group
• Lonza Group AG
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceuticals Industries Ltd.
• Zealand Pharma A/S

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145